Mecasermin

Mecasermin
Clinical data
AHFS/Drugs.com Monograph
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration		 Subcutaneous
ATC code H01AC03 (WHO)
Legal status
Legal status
Identifiers
CAS Number 68562-41-4 N
DrugBank DB01277 N
ChemSpider none
UNII 7GR9I2683O YesY
KEGG D04870 N
ChEMBL CHEMBL1201716 N
Chemical and physical data
Formula C331H512N94O101S7
Molar mass 7648.67 g/mol
 NYesY (what is this?)  (verify)

Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]

This drug is not to be confused with mecasermin rinfabate (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.

References

  1. ↑ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186Freely accessible. PMID 19707272.
  2. ↑ "Increlex". Drugs.com. Retrieved 10 January 2010.



This article is issued from Wikipedia - version of the 10/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.